GordonLPhillipsMD
Oncology • Winston Salem, NCProfessor, Medicine, University of Rochester School of Medicine & Dentistry
Dr. Phillips is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
S Hawthorne Rd
Winston Salem, NC 27157Phone+1 336-713-5440Fax+1 336-713-5445
Education & Training
University of North Carolina HospitalsResidency, Internal Medicine, 1972 - 1974
University of Oklahoma Health Sciences CenterInternship, Internal Medicine, 1971 - 1972- University of Oklahoma College of MedicineClass of 1971
Certifications & Licensure
NY State Medical License 2002 - Present
NC State Medical License 2019 - 2024
KY State Medical License 1995 - 2009
MD State Medical License 2000 - 2003
IL State Medical License 1977 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Start of enrollment: 2005 Jul 01
- Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer Start of enrollment: 2003 Dec 01
- Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease Start of enrollment: 2009 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 23 citationsA Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body IrradiationJane L. Liesveld, Gordon L. Phillips, Michael Becker, Louis S. Constine, Jonathan W. Friedberg
Biology of Blood and Marrow Transplantation. 2013-12-01 - 20 citationsA randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.William I. Bensinger, Pamela S. Becker, Ted Gooley, Thomas R. Chauncey, David G. Maloney
Bone Marrow Transplantation. 2016-01-01 - 15 citationsHigh-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years LaterHillard M. Lazarus, Gordon L. Phillips, Roger H. Herzig, David D. Hurd, Steven N. Wolff
Journal of Clinical Oncology. 2008-05-10
Journal Articles
- Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
